Connor, Clark & Lunn Investment Management (CC&L)
KRON

Connor, Clark & Lunn Investment Management (CC&L)’s Kronos Bio KRON Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-23,144
Closed -$39.8K – 1453
2023
Q2 		$39.8K Sell
23,144
-4,474
-16% -$7.1K ﹤0.01% 1277
2023
Q1 		$40.3K Buy
27,618
+1,895
+7% +$3.63K ﹤0.01% 1197
2022
Q4 		$41.7K Buy
+25,723
New +$59.2K ﹤0.01% 1155

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s KRON Position: Q3 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Kronos Bio (KRON) in Q3 2023, closing a stake of 23,144 shares — an estimated $39.8K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in KRON in Q4 2022 and held it in 3 quarters. The position peaked at $41.7K in Q4 2022. 63 funds tracked by Wall St. Rank hold KRON as of Q3 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Kronos Bio position as of Q3 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 23,144 Kronos Bio shares in Q3 2023, an estimated $39.8K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Kronos Bio in Q4 2022 and held it in 3 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Kronos Bio position peaked at $41.7K in Q4 2022.
  • 63 funds tracked by Wall St. Rank held Kronos Bio as of Q3 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2023, filed 13 Nov 2023.